Adam Ponedal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Adam Ponedal has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Amy S. Paller
Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago; Division of Dermatology, Ann & Robert H. Lurie Children's Hospital, Chicago
2 shared publications - Chad Alexander Mirkin
Department of Chemistry Northwestern University Evanston Illinois USA
2 shared publications Anthony J. Sprangers
International Institute for Nanotechnology, Northwestern University, Evanston, Illinois 60208, United States
1 shared publication- Brian Meckes
Department of Biomedical Engineering, University of North Texas, 3940 N Elm St., Denton, TX 76207, USA
1 shared publication - Chenjie Xu
City University of Hong Kong
1 shared publication Daniel C. S. Lio
School of Chemical and Biomedical Engineering, Nanyang Technological University, Singapore, 639798
1 shared publication
Latest Publications
- 1 June 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (6) , 1428-1437.e8
Epidermal SR-A Complexes Are Lipid Raft Based and Promote Nucleic Acid Nanoparticle Uptake
- 1 June 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (6) , 1428-1437.e8
Epidermal SR-A Complexes Are Lipid Raft Based and Promote Nucleic Acid Nanoparticle Uptake
- 13 November 2020
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 3 (12) , 8603-8610
Attenuation of Abnormal Scarring Using Spherical Nucleic Acids Targeting Transforming Growth Factor Beta 1
Abnormal scarring is a consequence of dysregulation in the wound healing process, with limited options for effective and noninvasive therapies. Given the ability of spherical nucleic acids (SNAs) to penetrate skin and regulate gene expression within, we investigated whether gold-core SNAs (AuSNAs) and liposome-core SNAs (LSNAs) bearing antisense oligonucleotides targeting transforming growth factor beta 1 (TGF-β1) can function as a topical therapy for scarring. Importantly, both SNA constructs appreciably downregulated TGF-β1 protein expression in primary hypertrophic and keloid scar fibroblasts in vitro. In vivo, topically applied AuSNAs and LSNAs downregulated TGF-β1 protein expression levels and improved scar histology as determined by the scar elevation index. These data underscore the potential of SNAs as a localized, self-manageable treatment for skin-related diseases and disorders that are driven by increased gene expression.
- 13 November 2020
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 3 (12) , 8603-8610
Attenuation of Abnormal Scarring Using Spherical Nucleic Acids Targeting Transforming Growth Factor Beta 1
Abnormal scarring is a consequence of dysregulation in the wound healing process, with limited options for effective and noninvasive therapies. Given the ability of spherical nucleic acids (SNAs) to penetrate skin and regulate gene expression within, we investigated whether gold-core SNAs (AuSNAs) and liposome-core SNAs (LSNAs) bearing antisense oligonucleotides targeting transforming growth factor beta 1 (TGF-β1) can function as a topical therapy for scarring. Importantly, both SNA constructs appreciably downregulated TGF-β1 protein expression in primary hypertrophic and keloid scar fibroblasts in vitro. In vivo, topically applied AuSNAs and LSNAs downregulated TGF-β1 protein expression levels and improved scar histology as determined by the scar elevation index. These data underscore the potential of SNAs as a localized, self-manageable treatment for skin-related diseases and disorders that are driven by increased gene expression.